我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

扩张型心肌病治疗手段的进展

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2016年第4期
页码:
488-491
栏目:
综述
出版日期:
2016-04-01

文章信息/Info

Title:
Advances in treatment of dilated cardiomyopathy
作者:
高晓飞1; 许轶洲2
(1.浙江中医药大学第二临床医学院，浙江 杭州 310053；
2.杭州市第一人民医院心血管内科，浙江 杭州 310006)
Author(s):
GAO Xiao-fei1;  XU Yi-zhou2
(1.Second Clinical Medicine of Zhejiang Chinese Medical University, Hangzhou 310053, Zhejiang, China；
2.Department of Cardiology, First People’s Hospital of Hangzhou City, Hangzhou 310006, Zhejiang, China)
关键词:
扩张型心肌病 ; 治疗; 研究进展; 综述
Keywords:
dilated cardiomyopathy;  therapy;  progress;  review
分类号:
R542.2
DOI:
-
文献标识码:
A
摘要:
扩张型心肌病（DCM）定义为单侧或双侧心腔扩大，伴有心肌肥厚，心肌收缩功能减退，伴或不伴有心力衰竭。目前该病发病率高，病因不明，致死率较高，无特效治疗手段，预后极差，严重危害着人类的健康。为此，本文针对DCM目前的治疗方法进行系统的综述。
Abstract:
Dilated cardiomyopathy (DCM) is defined as a unilateral or bilateral expanded chambers of the heart accompanied by cardiac hypertrophy and myocardial systolic dysfunction, with or without heart failure. The incidence of DCM increases gradually, with the cause being unknown and without specific treatment. Mortality rate is higher and prognosis is poorer, and human health is being seriously compromised. This article systematically reviews current methods of treatment for DCM.

参考文献/References

[1]Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee;Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups;and Council on Epidemiology and Prevention[J].Circulation,2006,113(14):1807-1816.
[2]Taylor DO,Edwards LB,Boucek MM,et al.Registry of the International Society for Heart and Lung Transplantation:twenty-fourth official adult heart transplant report--2007[J].J Heart Lung Transplant,2007,26(8):769-781.
[3]Spinarova L,Spinar J.Pharmacotherapy of dilated cardiomyopathy[J].Curr Pharm Des,2015, 21(4):449-458.
[4]Yancy CW, Jessup M,Bozkurt B,et al.2013 ACCF/AHA guideline for the management of heart failure:a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J].Circulation,2013,128(16):e240-e327.
[5]Kaya MG,Sarli B,Akpek M,et al.Evaluation of beta-blockers on left ventricular dyssynchrony and reverse remodeling in idiopathic dilated cardiomyopathy: A randomized trial of carvedilol and metoprolol[J].Cardiol J,2014,21(4):434-441.
[6]Matsumura Y,Hoshikawa-Nagai E,Kubo T,et al.Prediction of left ventricular reverse remodeling after therapy with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and beta blockers in patients with idiopathic dilated cardiomyopathy[J]. Cardiovasc Ultrasound,2015,13:14.
[7]Hu LJ,Chen YQ,Deng SB,et al.Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure:a systematic review and meta-analysis[J].Br J Clin Pharmacol,2013,75(5):1202-1212.
[8]Traynor K.Ivabradine approved for stable chronic heart failure[J].Am J Health Syst Pharm,2015,72(11):896.
[9]Utter MS,Ryba DM,Li BH,et al.Omecamtiv mecarbil,a cardiac myosin activator, increases Ca2+-sensitivity in myofilaments with a dilated cardiomyopathy mutant tropomyosin E54K[J].J Cardiovasc Pharmacol,2015,Jun 9.[Epub ahead of print].
[10]Carmo P,Nogueira G,Anjos R,et al.[Upgrading to biventricular pacing for dilated cardiomyopathy following right ventricular pacing in a young patient][J].Rev Port Cardiol,2012,31(1):43-47.
[11]Grimm W,Timmesfeld N,Efimova E.Left ventricular function improvement after prophylactic implantable cardioverter-defibrillator implantation in patients with non-ischaemic dilated cardiomyopathy[J].Europace,2013,15(11):1594-1600.
[12]Pezawas T,Diedrich A,Winker R,et al.Multiple autonomic and repolarization investigation of sudden cardiac death in dilated cardiomyopathy and controls[J].Circ Arrhythm Electrophysiol,2014,7(6):1101-1108.
[13]Buckberg GD,Athanasuleas CL,Wechsler AS,et al.The STICH trial unravelled[J].Eur J Heart Fail,2010,12(10):1024-1027.
[14]Lee RJ,Hinson A,Helgerson S,et al.Polymer-based restoration of left ventricular mechanics[J].Cell Transplant,2013,22(3):529-533.
[15]Hoshino J,Fukada Y,Hirota M,et al.[Preserving autologous heart operation for dilated cardiomyopathy][J].Kyobu Geka,2013,66(1):31-36.
[16]Mangini S,Alves BR,Silvestre OM,et al.Heart transplantation: review[J].Einstein(Sao Paulo),2015,13(2):310-318.
[17]Mancini D,Colombo PC.Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant[J].J Am Coll Cardiol,2015,65(23):2542-2555.
[18]Gho JM,Kummeling GJ,Koudstaal S,et al.Cell therapy,a novel remedy for dilated cardiomyopathy? A systematic review[J].J Card Fail,2013,19(7):494-502.
[19]Martino HF,Oliveira PS,Souza FC,et al.A safety and feasibility study of cell therapy in dilated cardiomyopathy[J].Braz J Med Biol Res,2010,43(10):989-995.
[20]Vrtovec B,Poglajen G,Sever M,et al.CD34+ stem cell therapy in nonischemic dilated cardiomyopathy patients[J].Clin Pharmacol Ther,2013,94(4):452-458.
[21]Zakliaz'Minskaia EV,Chapurnykh AV,Voronina TS,et al.Dilated cardiomyopathy caused by p E446K mutation in SCN5A gene[J].Kardiologiia,2014,54(3):92-96.
[22]Mann SA,Castro ML,Ohanian M,et al.R222Q SCN5A mutation is associated with reversible ventricular ectopy and dilated cardiomyopathy[J].J Am Coll Cardiol,2012,60(16):1566-1573.
[23]Yu SY,Liu L,Li P,et al.Rapamycin inhibits the mTOR/p70S6K pathway and attenuates cardiac fibrosis in adriamycin-induced dilated cardiomyopathy[J].Thorac Cardiovasc Surg,2013,61(3):223-228.
[24]Quattrocelli M,Crippa S,Montecchiani C,et al.Long-term miR-669a therapy alleviates chronic dilated cardiomyopathy in dystrophic mice[J].J Am Heart Assoc,2013,2(4):e000284.
[25]Kawai C,Matsumori A.Dilated cardiomyopathy update:infectious-immune theory revisited[J].Heart Fail Rev,2013,18(6):703-714.
[26]Zhu ZF,Tang TT,Dong WY,et al.Defective circulating CD4+LAP+regulatory T cells in patients with dilated cardiomyopathy[J].J Leukoc Biol,2015,97(4):797-805.

备注/Memo

备注/Memo:
收稿日期：2015-07-28.
通讯作者：许轶洲，主任医师，主要从事心脏起搏与电生理研究 Email:qqyzxu@hotmail.com
作者简介：高晓飞，硕士生 Email:mage0311@163.com
更新日期/Last Update: 2016-04-01